fluorodeoxyglucose f18 has been researched along with Fowl Paralysis in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avigdor, A; Ben-Haim, S; Chikman, B; Davidson, T; Goshen, E; Kedmi, M; Komisar, O; Lidar, M; Tzila Zwas, S | 1 |
| Daher, A; Kamiya-Matsuoka, C; Woodman, K | 1 |
| Gildersleeve, K; Hormozdi, B; Kamiya-Matsuoka, C; Manning, JT; Shroff, S; Woodman, KH | 1 |
| Bhattacharya, A; Biswal, CK; Mittal, BR; Prabhakar, S; Shukla, J; Vatsa, R | 1 |
| Clucas, D; Khoo, C; Lau, E; Lim, AT; Parameswaran, BK | 1 |
| de Jong, A; de Keizer, B; Hoekstra, OS; Mous, R; Nievelstein, RA; van Dongen, GA | 1 |
| Bund, C; Fohrer, C; Heimburger, C; Kremer, S; Namer, IJ; Trensz, P | 1 |
| Benjamin, A; Chateil, JF; de Clermont-Gallerande, H; de Vaugelade, C; Ducassou, S; Fernandez, P; Meyer, M; My Duyen Tiphaine, A | 1 |
8 other study(ies) available for fluorodeoxyglucose f18 and Fowl Paralysis
| Article | Year |
|---|---|
FDG PET-CT evaluation in neurolymphomatosis: imaging characteristics and clinical outcomes.
Topics: Adult; Aged; Aged, 80 and over; Animals; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Interpretation, Computer-Assisted; Image Processing, Computer-Assisted; Male; Marek Disease; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Young Adult | 2018 |
Patient With 2 Hematologic Malignancies Presenting as Neurolymphomatosis.
Topics: Aged; Animals; Female; Fluorodeoxyglucose F18; Hematologic Neoplasms; Humans; Magnetic Resonance Imaging; Marek Disease; Peripheral Nerves; Positron-Emission Tomography | 2018 |
Neurolymphomatosis: a case series of clinical manifestations, treatments, and outcomes.
Topics: Adult; Aged; Animals; Birds; Brachial Plexus; Female; Fluorodeoxyglucose F18; Humans; Immunoglobulins, Intravenous; Magnetic Resonance Imaging; Male; Marek Disease; Middle Aged; Plasma Exchange; Positron-Emission Tomography; Treatment Outcome | 2014 |
Fluorothymidine PET/CT in neurolymphomatosis.
Topics: Animals; Biopsy; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Marek Disease; Middle Aged; Multimodal Imaging; Peripheral Nervous System Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sciatic Neuropathy; Tomography, X-Ray Computed | 2015 |
Neurolymphomatosis: MRI and (18) FDG-PET features.
Topics: Adult; Aged; Aged, 80 and over; Animals; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Marek Disease; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals | 2016 |
(89) Zr-rituximab PET/CT to detect neurolymphomatosis.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Biopsy; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Marek Disease; Middle Aged; Phenotype; Positron Emission Tomography Computed Tomography; Rituximab | 2016 |
FDG PET to Diagnose Neurolymphomatosis in a Case of Triple-Hit B-Cell Lymphoma.
Topics: Animals; Fluorodeoxyglucose F18; Humans; Lymphoma, B-Cell; Magnetic Resonance Imaging; Male; Marek Disease; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography | 2017 |
FDG PET/CT in Pediatric Neurolymphomatosis.
Topics: Animals; Bone Neoplasms; Child; Female; Fluorodeoxyglucose F18; Humans; Marek Disease; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2017 |